{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:14:36Z","timestamp":1788448476914,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Special Research Foundation of the National Nature Science Foundation of China","award":["82273476, 81972262"],"award-info":[{"award-number":["82273476, 81972262"]}]},{"name":"Grant from Guangdong Science and Technology Department","award":["2015B050501004\uff0c2017B030314026"],"award-info":[{"award-number":["2015B050501004\uff0c2017B030314026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03703-7","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:51:08Z","timestamp":1740725468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and conversion outcome of chemotherapy combined with PD-1 inhibitor for patients with unresectable or recurrent gallbladder carcinoma: a real-world exploratory study"],"prefix":"10.1186","volume":"23","author":[{"given":"Qin-qin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-fang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-ni","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"5","key":"3703_CR1","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/s1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol May. 2021;22(5):690\u2013701. https:\/\/doi.org\/10.1016\/s1470-2045(21)00027-9","journal-title":"Lancet Oncol May"},{"key":"3703_CR2","doi-asserted-by":"publisher","unstructured":"Ishihara S, Horiguchi A, Miyakawa S, Endo I, Miyazaki M, Takada T. Mar. Biliary tract cancer registry in Japan from 2008 to 2013. Journal of hepato-biliary-pancreatic sciences. 2016;23(3):149\u2013\u200957. https:\/\/doi.org\/10.1002\/jhbp.314","DOI":"10.1002\/jhbp.314"},{"key":"3703_CR3","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.ctrv.2019.101936","volume":"84","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Edeline J, McNamara MG, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev Mar. 2020;84:101936. https:\/\/doi.org\/10.1016\/j.ctrv.2019.101936","journal-title":"Cancer Treat Rev Mar"},{"issue":"9","key":"3703_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.Cd-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New Horizons for Precision Medicine in biliary tract cancers. Cancer Discovery Sep. 2017;7(9):943\u201362. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0245","journal-title":"Cancer Discovery Sep"},{"issue":"14","key":"3703_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"8","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med Apr. 2010;8(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med Apr"},{"issue":"4","key":"3703_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"10","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J cancer Aug. 2010;10(4):469\u201374. https:\/\/doi.org\/10.1038\/sj.bjc.6605779","journal-title":"Br J cancer Aug"},{"issue":"5","key":"3703_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","volume":"1","author":"AB Benson","year":"2021","unstructured":"Benson AB, D\u2019Angelica MI, Abbott DE, et al. Hepatobiliary cancers, Version 2.2021, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Cancer Network: JNCCN May. 2021;1(5):541\u201365. https:\/\/doi.org\/10.6004\/jnccn.2021.0022","journal-title":"J Natl Compr Cancer Network: JNCCN May"},{"issue":"12","key":"3703_CR8","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/jamaoncol.2018.3277","volume":"1","author":"V Sahai","year":"2018","unstructured":"Sahai V, Catalano PJ, Zalupski MM, et al. Nab-Paclitaxel and Gemcitabine as First-line treatment of Advanced or Metastatic Cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol Dec. 2018;1(12):1707\u201312. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3277","journal-title":"JAMA Oncol Dec"},{"issue":"12","key":"3703_CR9","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"1","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol Dec. 2019;1(12):1950\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz402","journal-title":"Ann Oncol Dec"},{"key":"3703_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","volume":"123","author":"A Sharma","year":"2019","unstructured":"Sharma A, Kalyan Mohanti B, Pal Chaudhary S, et al. Modified gemcitabine and oxaliplatin or gemcitabine\u2009+\u2009cisplatin in unresectable gallbladder cancer: results of a phase III randomised controlled trial. Eur J Cancer Dec. 2019;123:162\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2019.10.004","journal-title":"Eur J Cancer Dec"},{"key":"3703_CR11","doi-asserted-by":"publisher","unstructured":"Chen X, Wang D, Liu J, et al. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes. J Immunotherapy cancer Nov. 2021;9(11). https:\/\/doi.org\/10.1136\/jitc-2021-003214","DOI":"10.1136\/jitc-2021-003214"},{"key":"3703_CR12","doi-asserted-by":"publisher","unstructured":"Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and other predictors of response to Immune checkpoint inhibitors in biliary Tract Cancer. Cancers Feb. 2021;1(3). https:\/\/doi.org\/10.3390\/cancers13030558","DOI":"10.3390\/cancers13030558"},{"key":"3703_CR13","doi-asserted-by":"publisher","first-page":"175883592110365","DOI":"10.1177\/17588359211036544","volume":"13","author":"SP Hack","year":"2021","unstructured":"Hack SP, Verret W, Mulla S, et al. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Therapeutic Adv Med Oncol. 2021;13:17588359211036544. https:\/\/doi.org\/10.1177\/17588359211036544","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"2","key":"3703_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","volume":"72","author":"RK Kelley","year":"2020","unstructured":"Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol Feb. 2020;72(2):353\u201363. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.009","journal-title":"J Hepatol Feb"},{"key":"3703_CR15","doi-asserted-by":"publisher","unstructured":"Chen X, Wu X, Wu H, et al. Camrelizumab plus Gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer Nov. 2020;8(2). https:\/\/doi.org\/10.1136\/jitc-2020-001240","DOI":"10.1136\/jitc-2020-001240"},{"key":"3703_CR16","doi-asserted-by":"publisher","unstructured":"Feng K, Liu Y, Zhao Y, et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J Immunother Cancer Jun. 2020;8(1). https:\/\/doi.org\/10.1136\/jitc-2019-000367","DOI":"10.1136\/jitc-2019-000367"},{"issue":"8","key":"3703_CR17","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, He AR, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced biliary tract Cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM Evid"},{"issue":"11","key":"3703_CR18","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/ijc.33751","volume":"1","author":"X Chen","year":"2021","unstructured":"Chen X, Qin S, Gu S, et al. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: a multicenter, phase 2 trial. Int J Cancer Dec. 2021;1(11):1944\u201354. https:\/\/doi.org\/10.1002\/ijc.33751","journal-title":"Int J Cancer Dec"},{"issue":"8","key":"3703_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/s2468-1253(19)30086-x","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol Aug. 2019;4(8):611\u201321. https:\/\/doi.org\/10.1016\/s2468-1253(19)30086-x","journal-title":"Lancet Gastroenterol Hepatol Aug"},{"key":"3703_CR20","doi-asserted-by":"publisher","first-page":"648068","DOI":"10.3389\/fonc.2021.648068","volume":"11","author":"M Gou","year":"2021","unstructured":"Gou M, Zhang Y, Liu T, et al. PD-1 inhibitors could improve the efficacy of Chemotherapy as First-Line treatment in biliary tract cancers: a propensity score matching based analysis. Front Oncol. 2021;11:648068. https:\/\/doi.org\/10.3389\/fonc.2021.648068","journal-title":"Front Oncol"},{"issue":"12","key":"3703_CR21","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1111\/jgh.15668","volume":"36","author":"S Zhao","year":"2021","unstructured":"Zhao S, Guo XG, Zhang D, et al. First-line chemotherapy or in combination with programmed cell death protein-1 antibody in patients with metastatic or recurrent biliary tract cancer. J Gastroenterol Hepatol Dec. 2021;36(12):3541\u20137. https:\/\/doi.org\/10.1111\/jgh.15668","journal-title":"J Gastroenterol Hepatol Dec"},{"issue":"9","key":"3703_CR22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet Sep. 2015;47(9):1003\u201310. https:\/\/doi.org\/10.1038\/ng.3375","journal-title":"Nat Genet Sep"},{"issue":"4","key":"3703_CR23","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/hep.31862","volume":"74","author":"JG Yoon","year":"2021","unstructured":"Yoon JG, Kim MH, Jang M, et al. Molecular characterization of biliary Tract Cancer predicts chemotherapy and programmed death 1\/Programmed death-ligand 1 blockade responses. Hepatol (Baltimore Md) Oct. 2021;74(4):1914\u201331. https:\/\/doi.org\/10.1002\/hep.31862","journal-title":"Hepatol (Baltimore Md) Oct"},{"key":"3703_CR24","doi-asserted-by":"publisher","first-page":"872295","DOI":"10.3389\/fimmu.2022.872295","volume":"13","author":"N Principe","year":"2022","unstructured":"Principe N, Aston WJ, Hope DE, et al. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer models identifies Additive combinations. Front Immunol. 2022;13:872295. https:\/\/doi.org\/10.3389\/fimmu.2022.872295","journal-title":"Front Immunol"},{"issue":"10","key":"3703_CR25","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1111\/cas.13337","volume":"108","author":"Y Iida","year":"2017","unstructured":"Iida Y, Harashima N, Motoshima T, Komohara Y, Eto M, Harada M. Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models. Cancer Sci Oct. 2017;108(10):1974\u201384. https:\/\/doi.org\/10.1111\/cas.13337","journal-title":"Cancer Sci Oct"},{"key":"3703_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","volume":"10","author":"J Wu","year":"2018","unstructured":"Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett Apr. 2018;10:419:210\u201321. https:\/\/doi.org\/10.1016\/j.canlet.2018.01.050","journal-title":"Cancer Lett Apr"},{"issue":"6","key":"3703_CR27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"14","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of Conventional Chemotherapy and targeted Anticancer agents. Cancer Cell Dec. 2015;14(6):690\u2013714. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.012","journal-title":"Cancer Cell Dec"},{"issue":"6","key":"3703_CR28","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/s2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh DY, Lee KH, Lee DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol Jun. 2022;7(6):522\u201332. https:\/\/doi.org\/10.1016\/s2468-1253(22)00043-7","journal-title":"Lancet Gastroenterol Hepatol Jun"},{"issue":"9","key":"3703_CR29","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00262-019-02386-w","volume":"68","author":"D Sun","year":"2019","unstructured":"Sun D, Ma J, Wang J, et al. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunol Immunotherapy: CII Sep. 2019;68(9):1527\u201335. https:\/\/doi.org\/10.1007\/s00262-019-02386-w","journal-title":"Cancer Immunol Immunotherapy: CII Sep"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03703-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:51:16Z","timestamp":1740725476000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03703-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3703"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03703-7","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Sun Yat-sen Memorial Hospital. The Ethics Committee of Sun Yat-sen Memorial Hospital waived the requirement for written informed consent for this study due to its retrospective nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}